Literature DB >> 6801612

Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB.

P Hechtman, B A Gordon, N M Ng Ying Kin.   

Abstract

A patient is described whose clinical course and pathologic features, including massive brain storage of GM2 ganglioside in grey matter, are identical with those of classical Tay-Sachs disease despite normal levels of beta -N-acetyl hexosaminidase and normal isozyme distribution. The kinetic properties and thermolability of the patient's hexosaminidase are normal. Crude extracts of a postmortem sample of patient's liver can catalyze the hydrolysis of 5.1 pmoles of labeled GM2 ganglioside/16 h/mg of protein (control liver = 69.9 pmoles/16 h/mg). Addition of partially purified human liver hexosaminidase A activator protein stimulated the hydrolysis of substrate by the patients liver extract by 27-fold compared to 3-fold for control livers. Measurement of "activator" in enriched fractions of patient's and control liver showed a reduced (25-30% of control) amount of stimulation of hexosaminidase A catalyzed hydrolysis of GM2 ganglioside as well as of Asialo-GM2 ganglioside. The addition of sphingomyelin to reaction mixtures, which is known to inhibit surfactant stimulation of hexosaminidase A, reduced activation of hexosaminidase A by patient's liver preparation to undetectable levels. Polyacrylamide gel electrophoresis of enriched preparations of control and patient's liver showed a rapidly migrating protein band in control liver corresponding to the activator protein and the absence of this protein band in the patient's liver.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801612     DOI: 10.1203/00006450-198203000-00011

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  Evidence for two cDNA clones encoding human GM2-activator protein.

Authors:  S Nagarajan; H C Chen; S C Li; Y T Li; J M Lockyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

2.  Preliminary evidence for a processing error in the biosynthesis of Gaucher activator in mucolipidosis disease types II and III.

Authors:  E Ranieri; B Paton; A Poulos
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

3.  Presence of activator proteins for the enzymic hydrolysis of GM1 and GM2 gangliosides in normal human urine.

Authors:  Y T Li; I A Muhiudeen; R DeGasperi; Y Hirabayashi; S C Li
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

4.  The AB-variant of metachromatic leukodystrophy (postulated activator protein deficiency). Light and electron microscopic findings in a sural nerve biopsy.

Authors:  A F Hahn; B A Gordon; J J Gilbert; G G Hinton
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

5.  Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.

Authors:  K Inui; D A Wenger
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

6.  Effect of structural modifications of ganglioside GM2 on intra-molecular carbohydrate-to-carbohydrate interaction and enzymatic susceptibility.

Authors:  Yu-Teh Li; Su-Chen Li; Makoto Kiso; Hideharu Ishida; Laura Mauri; Laura Raimondi; Anna Bernardi; Sandro Sonnino
Journal:  Biochim Biophys Acta       Date:  2007-10-05

7.  Immunological evidence for deficiency in an activator protein for sulfatide sulfatase in a variant form of metachromatic leukodystrophy.

Authors:  K Inui; M Emmett; D A Wenger
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

8.  Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.

Authors:  K Inui; E E Grebner; L G Jackson; D A Wenger
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

9.  Differentiation of two variants of type-AB GM2-gangliosidosis using chromogenic substrates.

Authors:  Y T Li; Y Hirabayashi; S C Li
Journal:  Am J Hum Genet       Date:  1983-05       Impact factor: 11.025

10.  Variant of GM2-gangliosidosis with hexosaminidase A having a severely changed substrate specificity.

Authors:  H J Kytzia; U Hinrichs; I Maire; K Suzuki; K Sandhoff
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.